Compare Banco Santander SA (SAN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs TG Therapeutics Inc — how do they compare? Banco Santander SA trades at $13.74 (market cap $191.46B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Banco Santander SA is far larger — about 23.2× TG Therapeutics Inc's market cap, and Banco Santander SA pays a 2.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SAN | TGTX | |
|---|---|---|
Market Cap | $191.46B | $8.26B |
Sector | Financials | Health |
52-Week High | $14.37 | $59.06 |
52-Week Low | $8.40 | $26.39 |
Dividend Yield | 2.09% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
